WebDoctor Encyclopedia

Genitourinary

FH-deficient renal cell carcinoma

FH-deficient renal cell carcinoma is a rare, aggressive kidney cancer caused by loss of the fumarate hydratase enzyme, usually as part of the inherited HLRCC syndrome. Prompt surgery and family genetic testing are central to care.

Medically reviewed Last reviewed October 21, 2026

What is FH-deficient renal cell carcinoma?

FH-deficient renal cell carcinoma (FH-deficient RCC) is a rare and aggressive kidney cancer. Its cells have lost a working copy of an enzyme called fumarate hydratase (FH). FH normally helps cells turn food into energy as part of the Krebs cycle, the chain of chemical steps that runs inside the mitochondria. When FH stops working, a substance called fumarate builds up inside the cell, and this build-up pushes the cell towards uncontrolled growth.

Most people with this cancer were born with a faulty FH gene. This inherited condition is called hereditary leiomyomatosis and renal cell cancer (HLRCC). It also causes harmless smooth muscle lumps in the skin and, in women, early and often numerous fibroids of the womb. A smaller group of patients develop FH loss only inside the tumour, without an inherited fault.

The 2022 World Health Organization (WHO) classification lists FH-deficient RCC as a separate, molecularly defined kidney cancer. Before this change, many of these tumours were labelled “type 2 papillary RCC” or “unclassified RCC”. The new name helps pathologists spot the disease and prompts doctors to offer genetic testing to the patient and family (Degenhardt et al., 2025).

How it differs from other kidney cancers

Most kidney cancers are clear cell RCC. The common non-clear-cell types, such as papillary, chromophobe and collecting duct carcinoma, are covered on our page on non-clear-cell renal cell carcinoma. FH-deficient RCC can look like papillary or collecting duct cancer under the microscope, but it differs in three important ways:

  • It is driven by loss of the FH enzyme, which can be shown with special stains
  • It often spreads early, even when the kidney tumour is small
  • It is frequently linked to an inherited syndrome, so relatives may also be at risk

1. Key facts at a glance

Feature Details
Type of cancer Kidney cancer defined by loss of the fumarate hydratase enzyme
Inherited link Most cases occur in people with HLRCC (germline FH variant)
How common Rare; a small fraction of all kidney cancers
Typical age Often adults in their 30s and 40s; occasionally teenagers
Usual pattern A single tumour in one kidney, often with early spread
Key test Loss of FH staining and genetic testing for FH
Main treatment Prompt surgery with a wide margin
Advanced disease Anti-angiogenic drugs, immunotherapy combinations, or bevacizumab plus erlotinib
Outlook Good if found early; guarded once it has spread

2. Types

Inherited and non-inherited forms

Form Description What it means for the family
HLRCC-associated The patient carries an FH variant in every cell of the body First-degree relatives have a 50% chance of carrying it and should be offered testing
Sporadic (somatic only) FH is lost only in the tumour Relatives are not at increased risk from this cause

In one Chinese multicentre series of 77 people with FH-deficient RCC, 70 had an inherited FH change and seven had loss in the tumour only (Xu et al., 2023).

Patterns under the microscope

Pattern Notes
Papillary Finger-like fronds; once called type 2 papillary RCC
Tubulocystic Small tubes and cysts; a solid part often hides more aggressive tissue
Solid Sheets of cells
Cribriform Sieve-like spaces
Mixed Several patterns in one tumour are common
Condition Who is affected Notes
Cutaneous leiomyomas Men and women Firm, skin-coloured or reddish bumps, often painful with cold or touch
Uterine leiomyomas (fibroids) Women Often several, appearing at a young age
Kidney cysts Some carriers Need monitoring, as cancer may arise in or near them
Other tumours Rarely Adrenal and Leydig cell tumours have been reported

In a UK cohort of 185 people from HLRCC families, almost half had skin leiomyomas and about three in ten women had fibroids (Forde et al., 2020).

3. Causes and risk factors

The FH gene

The FH gene sits on chromosome 1. People with HLRCC inherit one faulty copy. Cancer develops when the second, healthy copy in a kidney cell is also damaged. This is a classic “two-hit” pattern seen in many inherited cancer syndromes.

Factor Notes
Inherited FH variant The main risk factor; passed on in an autosomal dominant way
Family history Kidney cancer at a young age, skin leiomyomas or early fibroids in relatives
Age Can occur from adolescence onwards
Sex Affects men and women
Lifestyle Smoking and obesity raise kidney cancer risk in general; no specific link to FH-deficient RCC is established

How likely is kidney cancer in an FH carrier?

Not everyone with HLRCC develops kidney cancer. An international expert group estimated the lifetime risk at about 15% (Menko et al., 2014). The UK cohort found a figure closer to 21% (Forde et al., 2020). The risk is therefore real but affects a minority of carriers.

Why does losing FH cause cancer?

When FH is absent, fumarate accumulates. High fumarate levels make the cell behave as though it is short of oxygen, even when it is not. This switches on growth signals and the formation of new blood vessels.

Fumarate also attaches to proteins, creating a chemical mark known as 2SC, which pathologists can stain for. These changes help explain why drugs that block blood vessel growth have activity against this cancer.

4. How does it look

On scans

Scan Typical findings
Ultrasound A solid or partly cystic kidney mass
CT scan A mass that may appear infiltrative, with enlarged lymph nodes in some patients
MRI Preferred for surveillance in HLRCC carriers; shows small lesions without radiation
PET-CT Tumours often take up glucose tracer strongly, which can help with staging

Under the microscope

Feature Description
Large nuclei Cells have big nuclei
Prominent nucleoli A large, pink-red nucleolus surrounded by a clear halo, sometimes compared to a viral inclusion
Growth pattern Papillary, tubulocystic, solid or cribriform areas, often mixed
Invasive edge Tumour cells infiltrate into surrounding kidney tissue

Special tests on the tissue

Test Typical result
FH immunostain Loss of FH protein in tumour cells
2SC immunostain Positive, showing fumarate build-up
Genetic testing of the tumour Shows FH alteration
Germline (blood or saliva) test Shows whether the FH change is inherited

5. Symptoms

Small tumours often cause no symptoms. In HLRCC carriers, they may be found on a screening MRI. Larger or advanced tumours may cause symptoms similar to other kidney cancers.

Common symptoms

  • Blood in the urine, which may appear pink, red or cola-coloured
  • Pain in the side or back that does not go away
  • A lump in the side or abdomen
  • Tiredness and unexplained weight loss

Less common symptoms

Symptom Possible cause
Persistent cough or breathlessness Spread to the lungs
Bone pain Spread to bone
Swollen lymph nodes Spread to nodes
Fever and night sweats Advanced disease
Painful skin bumps Skin leiomyomas, a clue to HLRCC
Heavy, painful periods at a young age Fibroids, a clue to HLRCC

When to seek medical advice

See a doctor if you notice blood in your urine, persistent pain in your side, or an unexplained lump. Tell your doctor if relatives have had kidney cancer at a young age, multiple skin bumps or early fibroids.

6. Diagnosis

Step What is done
Medical and family history Questions about skin lumps, fibroids and kidney cancer in relatives
Skin and pelvic examination Looks for leiomyomas
Blood and urine tests Kidney function, blood count, blood in urine
CT or MRI of the abdomen Shows the kidney mass and lymph nodes
CT of the chest Checks the lungs for spread
Biopsy or surgery Tissue diagnosis
FH and 2SC staining Confirms FH deficiency
Genetic counselling and germline test Confirms or excludes HLRCC

Staging

FH-deficient RCC is staged with the TNM system used for other kidney cancers.

Stage Simplified meaning
Stage I Tumour 7 cm or smaller, confined to the kidney
Stage II Larger than 7 cm, still confined to the kidney
Stage III Spread into major veins, the fat around the kidney, or nearby lymph nodes
Stage IV Spread beyond the fat layer or to distant organs

7. Treatment

Treatment should be planned at a specialist kidney cancer centre with experience in hereditary kidney cancer.

Surgery

Because FH-deficient RCC can spread early, experts advise prompt surgery. Approaches used for other inherited kidney tumours, such as waiting until a tumour reaches 3 cm, are not suitable here.

Aspect Recommendation
Timing Without delay once a suspicious lesion is found
Extent Removal with a wide margin, usually removal of the whole kidney
Partial nephrectomy Considered only in carefully selected small tumours
Lymph node removal May be considered, as nodes are often involved
Active surveillance of a known tumour Not recommended

The international HLRCC consensus advised wide-margin excision and consideration of lymph node dissection (Menko et al., 2014). A wide margin is favoured because the tumour tends to invade, which makes kidney-sparing surgery riskier (Degenhardt et al., 2025).

Treatment for advanced disease

There is no single standard drug treatment, and much of the evidence comes from small retrospective studies. A clinical trial is a good option where available.

Treatment Evidence summary
Anti-angiogenic tablets (cabozantinib, sunitinib and others) In a European series, response rates were higher and treatment lasted longer than with checkpoint inhibitors or mTOR inhibitors (Carril-Ajuria et al., 2021)
Bevacizumab plus erlotinib Targets blood vessel and growth signals; reported activity in HLRCC-related cancer (Degenhardt et al., 2025)
Immunotherapy plus a tyrosine kinase inhibitor In a Chinese series, this combination was linked to better survival than bevacizumab plus erlotinib (Xu et al., 2023)
Checkpoint inhibitors alone Lower response rates in the European series
mTOR inhibitors Little benefit observed
Radiotherapy Used to relieve symptoms from bone or brain spread

The European study reported a median overall survival of about 44 months from the start of drug treatment, which was longer than many experts had expected (Carril-Ajuria et al., 2021).

Side effects

Treatment Common side effects
Surgery Pain, wound problems, reduced kidney function
Tyrosine kinase inhibitors Diarrhoea, high blood pressure, hand-foot skin reactions, tiredness
Bevacizumab High blood pressure, protein in urine, bleeding risk
Erlotinib Acne-like rash, diarrhoea
Immunotherapy Immune inflammation of the skin, gut, liver, lungs or hormone glands

8. Outlook (prognosis)

The outlook depends mostly on the stage at diagnosis. In the UK HLRCC cohort, people diagnosed at stage 1 or 2 lived much longer than those found at stage 3 or 4, and screening picked up some stage 1 tumours (Forde et al., 2020). This is the main reason why carriers are offered regular scans.

Factor Effect on outlook
Small tumour found on screening Best outcome
Spread to lymph nodes Higher risk of recurrence
Distant spread Poorer outlook, though some people live for several years with treatment
Response to drug treatment Better survival in responders

Even after successful surgery, carriers keep a lifelong risk of a new tumour in the other kidney, so follow-up continues (Degenhardt et al., 2025).

9. Follow-up and surveillance

After treatment

Check Typical timing
CT of chest, abdomen and pelvis Every 3-6 months at first, then less often
Kidney function tests Regularly, especially with one kidney
Blood pressure At every visit
Skin and gynaecological review As needed for HLRCC features

Screening for relatives and carriers

Recommendation Details
Genetic counselling For all first-degree relatives
Predictive genetic testing Can be offered from about 8-10 years of age
Kidney MRI Usually yearly, starting in childhood or adolescence
Skin and pelvic checks For leiomyomas and fibroids

The consensus group suggested yearly abdominal MRI and noted that the benefits and drawbacks of screening children should be discussed with each family (Menko et al., 2014).

10. Living with FH-deficient renal cell carcinoma

  • Keep all surveillance appointments, even when you feel well
  • Protect your remaining kidney by avoiding drugs that can harm it, such as regular use of anti-inflammatory painkillers, unless your doctor agrees
  • Control blood pressure and stay well hydrated
  • Tell relatives about the genetic result so they can seek advice
  • Plan pregnancies with your team; fibroids and genetics may need discussion
  • Ask about clinical trials, as research into this cancer is active
  • Seek support from kidney cancer charities and genetic support groups

Coping with a hereditary diagnosis

Learning that a cancer is inherited can raise worries about children and other relatives. Genetic counsellors can explain the result, discuss testing for family members and help with the timing of conversations. Many families find that knowing about HLRCC early allows them to take control through regular screening.

11. Frequently asked questions

Question Answer
Is FH-deficient RCC always inherited? No, but most cases are; genetic testing is recommended for everyone diagnosed
Will my children get it? Each child has a 50% chance of inheriting the variant; not all carriers develop cancer
Why not wait and watch a small tumour? This cancer can spread even when small, so prompt removal is advised
Can I keep part of my kidney? Sometimes, but a wide margin usually takes priority
Are skin bumps dangerous? Skin leiomyomas are benign, though they can be painful
What is 2SC? A chemical mark left by fumarate build-up, used as a stain to help diagnosis
Is there a cure for advanced disease? Not usually, but drugs can control it for a time

12. Questions to ask your care team

  • Has my tumour been tested for FH loss and 2SC?
  • Have I had germline genetic testing, and what does it show?
  • Which relatives should be offered testing?
  • Do you recommend removing the whole kidney or part of it?
  • Will my lymph nodes be removed?
  • What scans will I need, and how often?
  • If the cancer spreads, which drug treatments or trials are available?

Resources

  1. Carril-Ajuria, L. et al. (2021) ‘Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma’, European Journal of Cancer, 151, pp. 106-114.
  2. Degenhardt, J. et al. (2025) ‘The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma’, Nephrology Dialysis Transplantation, 40(7), pp. 1428-1432.
  3. Forde, C. et al. (2020) ‘Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals’, European Urology Oncology, 3(6), pp. 764-772.
  4. Menko, F.H. et al. (2014) ‘Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment’, Familial Cancer, 13(4), pp. 637-644.
  5. Xu, Y. et al. (2023) ‘Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma’, European Urology, 83(2), pp. 163-172.
  6. National Cancer Institute (2026) Genetics of Renal Cell Carcinoma (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq (Accessed: October 2026).
  7. National Cancer Institute (2026) Renal Cell Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.